RedHill Biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. RedHill has an experienced management team, Board of Directors and Advisory Board based in Israel, the US, Canada and Europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
Latest News
-
January 2nd, 2012
IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial -
November 23rd, 2011
Dr. Jeff Lehighton presents RedHill Biopharma on Bloomberg TV -
November 4th, 2011
RedHill Biopharma engages with CRO for potential pivotal trial with RHB-102 (prevention of nausea & vomiting in cancer patients) -
October 25th, 2011
RedHill Biopharma appoints Prof. Colm O’Morain, MD as Lead Investigator for the European Phase III trial with RHB-104 (Crohn’s) -
October 6th, 2011
RedHill Biopharma appoints Prof. David Y. Graham, MD as Lead Investigator for the US pivotal trial with RHB-104 (Crohn’s)
See More News